C&G Editor in Chief, Erin Harris

  1. CGT In 2023 With Cartesian Therapeutics, Poseida Therapeutics, REGENXBIO, And Spark Therapeutics 11/29/2022

    To better understand 2023’s most pressing issues in the cell and gene therapy space, I sought expert commentary from Cartesian Therapeutics’ Murat Kalayoglu, Poseida Therapeutics’ Mark Gergen, REGENXBIO’s Nina Hunter, and Spark Therapeutics’ Ron Philip.

  2. DTx Pharma And The Near-Term Future Of RNA Therapeutics 11/21/2022

    To learn more about the near-term future of RNA therapeutics, the advantages of short interfering RNA (siRNA) over other RNA therapeutics and more, I caught up with DTx Pharma's CEO Arthur Suckow.

  3. ICYMI: Cell & Gene Live, Evaluating Translational Research Tools For CGTs 11/17/2022

    Here's a breakdown of our most recent Cell & Gene Live Evaluating Translational Research Tools For CGTs, featuring industry experts Gregory Opiteck, Ph.D., VP, Head of Translational Sciences at Allogene Therapeutics and Douglas Sanders, Ph.D., VP, Head of Translational Medicine at AVROBIO.

  4. A Growing Emphasis On Gene Silencing 11/17/2022

    I chatted with Tom Payne, Laverock Therepeutics' Chief Operating Officer, about the company’s mission to utilize its Gene Editing induced Gene Silencing (GEiGS) technology, and its associated computational platform, to engineer induced pluripotent stem cells (iPSC)-derived cell therapies with improved efficacy, safety, and accessibility. 

  5. The Promising Future Of Oligonucleotides 10/31/2022

    Episode 35 of Cell & Gene: The Podcast features Dr. Michelle Mellion, PepGen’s SVP Head of Clinical Development at Cambridge, MA-based biotech PepGen. In it, Dr. Mellion talks all about the company’s oligonucleotide therapeutics that were developed to treat severe neuromuscular and neurologic diseases, such as Duchenne Muscular Dystrophy (DMD).

  6. Life Science Leader's Annual Industry Outlook Issue: What Didn't Make It To Print 10/25/2022

    Cell & Gene’s sister publication and fellow Life Science Connect resource, Life Science Leader magazine, is the essential business journal for life science executives who work for everything from emerging biotechs to Big Pharmas, aka you. 

  7. Meeting On The Mesa 2022: Big Pictures & Takeaways 10/18/2022

    Alliance for Regenerative Medicine (ARM)’s Meeting on the Mesa (MOTM) 2022 was held October 11-13, 2022 in Carlsbad, CA. The meeting was packed with good information, and I wanted to share with you just a few of the most important soundbites I gleaned from the event. So, whether you attended the event in person, or you want to know what you may have missed, here are some of the highlights from MOTM 2022.

  8. CGT 2023: A Look Ahead 10/7/2022

    Once a month, my Life Science Connect editorial colleagues and I meet to discuss the most pressing topics in our respective coverage areas to learn from each other and to address any overlaps (hint: there are always many overlapping issues). Fresh off our most recent meeting, I thought I’d share with you what we covered and what are just some of the topics and trends Cell & Gene will continue to cover into next year.

  9. Breakdown Of Cell & Gene Live: Advancements In Targeted mRNA Delivery 9/21/2022

    During our Cell & Gene Live, Advancements in Targeted mRNA Delivery, Dr. Murat Kalayoglu, CEO of Cartesian Therapeutics, Walter Strapps, Ph.D., Co-Founder and CEO of Carver Biosciences, and I spent the hour talking about the delivery of mRNA-based therapeutics. Our expert panelists discussed the specific challenges and opportunities in delivering conventional RNA therapeutics clinically, as well as the specific challenges and opportunities in delivering the RNA cell therapies clinically. You can view the full-length presentation here. For your convenience, we’ve broken down the hour into bite-size chunks based on the important topics we discussed throughout the hour.

  10. Capstan Therapeutics' Next Steps For In Vivo CAR Therapies 9/19/2022

    Capstan Therapeutics is a brand-new biotech company dedicated to developing and delivering precise in vivo cell engineering to patients. With $165 million in financing, Capstan Therapeutics aims to build on the foundational insights of leaders in mRNA and cell therapy from the University of Pennsylvania. Laura Shawver, Ph.D., leads the company as President and CEO, and on the heels of the biotech’s recent news, I caught up with her to learn more about the company’s plans for developing in vivo CAR therapies.